Protein-tyrosine phosphatase (F'TPase) activity in frozen human mammary primary carcinoma tissue sections has been quantitated using a modified histochemical assay. The im- 
Introduction
Protein-tyrosine phosphatases (PTPases) enzymatically catalyze the removal of phosphates that have been esterified to tyrosine residues in cell proteins; the reverse process of enzymatically catalyzed phosphorylation of tyrosine residues is mediated by protein-tyrosine kinases (PTKases). PTKases play a major role in the temporal regulation of cell processes mediated by reversible phosphorylation, such as cell growth, proliferation, and differentiation (15).
The amplification and/or overexpression of PTKase protooncogenes has been directly linked to the process of oncogenic cell transformation and tumorigenesis (17) . For example, the c-er6B-2 proto-oncogene receptor PTKase has been shown to (a) be amplified and/or overexpressed in approximately 30% of human mammary and ovarian carcinomas (11, 12, 16) , (b) instigate via plasmidmediated amplification the transformation of cultured NIH-3T3 cells (1, 2) , (c) be linked to the initiation of human mammary and cator for the identification of node-positive patients with these types of cancer who are at a high risk of relapse (11, 12, 16) .
Since PTPases play a major role in controlling the balance of tyrosine phosphorylation and dephosphorylation in cell proteins, PTPase activity may also be an important factor in the process that results in oncogenic cellular transformation and tumorigenesis initiated by aberrant PTKase activity (3). This hypothesis is supported by the observation that exposing NRK-1 cells in culture to sodium orthovanadate, an efficient inhibitor of PTF'ases, caused an increase in the cellular content of phosphotyrosine-containing proteins, as well as coincident phenotypic changes that are suggestive of transformation (5). Yet despite the large body of knowledge that exists concerning the role that aberrant PTKase activity plays in cell transformation and tumorigenesis, little is known concerning the role of the PTPases in these processes.
In an effort to determine if PTPase activity is proportionately increased in human mammary carcinoma in response to increased expression of the c-erbB-2 proto-oncogene protein-tyrosine kinase, we have compared the level of PTPase activity with the expression of the c-er6B-2 protein in tumor sections, as well as with established prognostic factors in mammary cancers. In this communication, we present a modified and improved histochemical assay for the measurement of total PTPase activity in human mammary tis-sues and provide evidence demonstrating that total PTPase activity is overexpressed in a large proportion of primary human mammary carcinoma tissues. However, this overexpression does not associate in a statistically significant manner with the overexpression of the c-erbB-2 proto-oncogene or with the grade or stage of disease.
Materials and Methods

Grosine-specz-c Phosphatase Histochemical Assay
Tyrosine-specific protein phosphatase activity was measured in primary human mammary carcinomas using a modification of the procedure described by Partanen and Pekonen (9). The modified protocol described here dramatically enhanced the observable reactivity of tyrosine phosphatasecontaining tissues, eliminated the background reactivity of tissues in the absence of substrate, and increased the stability and reliability of the assay.
Preparation of Tissue Sections. Tissue sections were isolated from primary human mammary carcinomas with various pathological diagnoses, normal human mammary tissues, and normal human kidney tissues obtained from patients undergoing surgical biopsy or resection at Duke University Medical Center. All procedures followed were in accordance with the ethical standards of the Committee on Human Experimentation of the Duke University Medical Center. Normal human kidney tissue was utilized to standardize the conditions of the histochemical assay since it is a rich source of tyrosine-specific phosphatase activity (9) . Tissue fragments were snapfrozen in liquid Nz immediately after surgery and stored at -7O'C until just before the preparation of sections. The fragments were then placed in OCT embedding medium (Miles; Elkhart, IN) and 12-pm serial sections were cut at -16'C on an A 0 Reichart cryostat (Buffalo, NY), placed on clean glass slides, and air dried for 1 hr at 22°C. Slides prepared in this manner were used immediately or rapidly frozen for storage at -2O' C for not longer than 48 hr. Serial sections of tissue from the same block were utilized for the immunohistochemical assay for c-erbB-2 as described below.
Preparation of Assay Reagents. All reagents for the preparation of stock solutions were obtained from Sigma (St Louis, MO) unless otherwise noted. Fresh stock solutions were prepared 1 hr before use in glass-double-distilled deionized water as follows: (A) 20 mM 0-phospho-ttyrosine (P-tyr) substrate and (D) 20 mM 0-phospho-cserine (P-ser) or 0-phospho-bthreonine (P-thr) substrate were prepared in 50 mM MES buffer, pH 6.0. Solutions B and E, respectively, were prepared by the dilution of 20 mM P-tyr, 20 mM P-ser, or 20 mM P-thr substrate solutions to 10 mM with 50 mM MES, pH 6.0. Solutions A, B. D, and E were then adjusted to pH 5.8 with 50 mM MES, pH 12.0. The PTPase-specific inhibitor sodium orthovanadate was prepared at a stock concentration of 10 mM in 50 mM MES, pH 6.0 (Solution C). Reaction buffer (Solution F; 3.5 mM lead nitrate in sodium citrate) was prepared by mixing equal volumes of 0.1 M trisodium citrate and 30 mM lead nitrate, adding 1.15 volumes of deionized water, and readjusting the pH to 6.2 using 0.1 M citrate buffer, pH 4.2.
Working solutions were then prepared by combining the stock solutions as follows: (a) negative control: equal volumes of solution F and 50 mM MES, pH 6.0; (b) PTPase activity: equal volumes of solutions F and A; (c) PTPase activity in the presence of FTF'ase-specific inhibitor: 10:9.5:0.5 vols FB:C, respectively; (d) PSTPase activity: equal volumes of solutions F and D; (e) PSTPase activity in the presence of PTPase-specific inhibitor: 10:9.5:0.5 vols FE:C, respectively.
Protein-Tyrosine Phosphatase Assay. PTPase activity was assayed in 12 pm tissue sections prepared as described. It is important to note that tissue sections were not chemically fixed before the assay, since chemical fixation dramatically decreased observable enzyme activity. Although drying tissue sections in air may denature active enzymes in the tissues, a comparison of air-drying and chemical fixation indicated that chemical fivation reduces observable PTPase activity by more than 90% (data not shown). Each assay for enzymatic activity in breast tissues contained a section of normal human kidney tissue as a positive control.
The assay was initiated by the addition of 400 pI of the appropriate working solution to the unfixed tissue section, followed by incubation of the slides in a humid chamber at 37°C for 4 hr. The slides were then washed four times for 5 min each in deionized water and developed for 1 min in 0.2% ammonium sulfide solution (Fisher, Fairlawn, NJ; diluted from 20% solution less than 5 min before use), followed by washing four times for 5 min each in deionized water for 20 min. The reaction was preserved by submerging the reacted tissue section in Crystal Mount aqueous mounting medium (Biomeda; Foster City, CA), dried at 37°C for 20 min, and permanently preserved with a coverslip using Protexx (Scientific Products; McGaw Park, IL). The level of PTPase activity was determined using normal mammary epithelium tissue as the negative control (value = and normal kidney tissue as the positive control (value = 3+), PTPase activity was then graded on a 0-3 + scale. The value for F'TPase activity in tumor sections was determined in areas of the stained section that corresponded to where hematoxylin and eosin staining indicated the presence of carcinoma.
Immunohistochemical Assay for c-erbB-2 Protein Expression
Automated immunohistochemical analysis was performed to quantify the expression of the c-erbB-2 receptor tyrosine kinase. Serial 4-pm sections of tissues were cut from the same regions of frozen blocks used for the histochemical assay of phosphatase activity to facilitate the analysis of the same tumor sections for phosphatase enzymatic reactivity and c-erbB-2 expression. The sections were placed on gelatin-coated slides, air-dried for 1 hr at 22'C. and fixed in 100% acetone for 10 min. The slides were then allowed to air-dry for 20 min and were loaded into a Cadenza Analyzer (Shandon; Pittsburgh, PA) for automated immunostaining (4). Fixed tissue sections were allowed to react with monoclonal antibody (MAb) TA-1 (Dupont, Boston, MA) for the detection of c-erbB-2 expression, antiepidermal growth factor receptor (EGFr) MAb (Amersham; Arlington Hts, IL), MAb AEl/AE3 (Boehringer Mannheim; Indianapolis, IN) for the detection of high and low molecular weight cytokeratin as a positive control tumor marker, or normal mouse IgGl (Coulter Clone; Hialeah, FL), used as a negative control. Tissue sections were utilized only if AEl/AE3 staining indicated the presence of carcinoma-specific cytokeratin. Values for c-erbB-2 protein expression were graded on a 0-4+ scale, with 0-1+ considered normal. In addition, serial sections from each tissue sample were prepared for morphological assessment using a hematoxylinlcosin stain (H & E; Armed Forces Institute of Histology Manual protocol).
Statistical Analysis
Values for grade and stage of disease, as well as the number of involved lymph nodes, were obtained from the Duke Health Information Service (DHIS). Grade was assessed on a 1-3 numerical system. Stage was assessed on a 1-4 numerical system. Contingency tables were utilized to examine the relationship between PTPase levels and categories of grade and stage of disease, as well as the level of expression of the c-erbB-2 proto-oncogene. Pvalues were determined using the Pearson chi-square statistic. Differences in survival durations among the PTPase groups were tested with the logrank statistic. 
Optimization of Assay Conditions
Preliminary histochemical assays of sections of human normal kidney tissues for PTPase activity based on published protocols (9) were unsatisfactory in our hands owing to the instability of the assay reagents in reaction buffer, high background staining in the absence of substrate (negative control), and faint staining in the presence of the P-tyr substrate that was inconsistently and incompletely inhibited by the PTPase-specific inhibitor sodium orthovanadate.
These disadvantages were overcome by (a) the use of MES buffer (pKa 6.15) instead of Tris buffer (pKa 8.30 ) for the preparation of substrate and inhibitor solutions to be used in reactions at pH 6.0, which is the optimal pH for this reaction (unlike MES buffer, Tris buffer can participate in reactions designed to assay protein-tyrosine phosphatase activity) and (b) the use of air-dried tissue sections without chemical fixation for the histochemical assays; chemical fixation reduced the intensity observed in assays of positive reactions and increased the level of background staining. The use of air-dried unfixed sections allowed for more sensitive differential grading of protein-tyrosine phosphatase staining, and completely eliminated background staining in the absence of P-tyr substrate or in the presence of the PSTPase substrates P-ser or P-thr. Typical results obtained utilizing the modified protocol to standardize staining with sections of the positive control human normal kidney are shown in Figures 1A-1E and 2A. Staining of primary mammary carcinoma tissue sections for PTPase activity was variable, and ranged from a slight increase over normal staining ( Figure 2B , 1+ reaction) to strong PTPase reactivity ( Figure 2C, 3 + reaction) . No visible reaction was observed in the absence of the P-tyr substrate or in the presence of the P-tyr substrate with 0.25 mM sodium orthovanadate inhibitor ( Figures 1A, and lE, respectively) . In addition, no reaction was observed with P-ser or P-thr used as substrate ( Figure IC) . Finally, thin sections of normal mammary tissue stained lightly (&I+), indicating very low PTPase activity, and no nuclear staining was evident in normal sections (data not shown). Therefore, this sensitive assay specifically detects the total protein-tyrosinephosphatase activity. The lack of nuclear staining in the normal tissue sections suggests that we are not observing staining in the nucleus as a result of substrate sticking to the nuclear structures. It is important to note that the total phosphatase activity measured in this assay may include any tyrosine-specific phosphatase activity that will enzymatically cleave P-tyr but not P-ser or P-thr, and which is inhibited by sodium orthovanadate.
IYlPase Activity in Human Mammary Carcinoma Tissues
PTPase activity and the expression of the c-er6B-2 proto-oncogene receptor were assayed in 53 primary human mammary carcinoma tumors by the methods described. The study cohort, consisting of frozen tumor sections chosen randomly from the Duke Breast Clinic Bank, represented 42 infiltrating ductal carcinomas, five lobular carcinomas, and three each medullary carcinomas and inflammatory carcinomas. Representation of infiltrating ductal carcinomas as the predominant tumor in the cohort is due to selection for these tumors by the participating clinic surgeons; the unusually large percentage of the tumors that are amplified and/or overexpressing the c-er6B-2 protein is a consequence of this bias in the banked tissues. For control purposes, PTPase activity in tumor sections was compared with the activity observed in normal human mammary tissues obtained at reduction mammoplasty. Normal mammary tissues displayed slight PTPase activity (value = &I+). In contrast, PTPase activity was found to be dramat'ically increased (value = 2 + or 3 + ) in 36/53 (67.9%) of the tumor sections. Analysis of PTPase activity by tumor type revealed the following: 27/42 (64.3%) of the infiltrating ductal carcinomas, 415 (80%) of the lobular carcinomas, 3/3 (100%)ofthemedullarycarcinomas, and 213 (66%) of the inflammatory carcinomas displayed increased phosphatase activity. In addition, PTPase activity was observed to be increased in areas of the tumor sections where hematoxylin and eosin staining of the sections revealed carcinoma to be present, and cells within a stained tumor section were predominantly homogeneous for the level of PTPase activity, with a small proportion of cells displaying variant levels of PTPase activity. Finally, PTPase activity was aberrantly high in the nuclei of cells as well as throughout the cytoplasm and cytoplasmic membrane of cells in tumor sections that displayed an overall increase in PTPase activity.
Relationship Between IYlPase Activity and Prognostic Indicators
It was of interest to determine if the level of PTPase activity observed in tumor sections was associated with grade and stage of dis- ease, the level of expression of the c-erbB-2 proto-oncogene receptor tyrosine kinase, and patient survival with a median time of follow-up of 23 months (range 1.0-36.2 months). Staining of c-erbB-2 proto-oncogene p185 glycoprotein expression was performed by automated immunohistochemistry using a monoclonal antibody to the extracellular domain of the protein, and ranged in primary mammary carcinoma sections from normal expression (&I+; data not shown) to strong overexpression of the protein (3+ reaction; Figure 2D ). Statistical analysis revealed that no significant relationship exists between the level of PTPase activity and categories of grade or stage of disease, or c-erbB-2 expression (Table l). Based on short follow-up, PTPase activity does not appear to be associated with survival duration (p = 0.45, logrank test). Of the 53 patients whose tumors were examined, ten (18.9%) have died from metastasis of the primary lesion, one (1.9%) has died with no evidence of disease, five (9.4%) remain alive with evidence of disease, and 37 (69.8%) show no evidence of disease to date. Finally, there is no significant association between the level of PTPase activity and the presence of metastasis to axillary lymph nodes (Table l). Twenty-eight of the 53 patients (52.8%) demonstrated metastasis to axillary lymph nodes, including 16 patients with four or more nodes involved. No association was found between PTPase activity and subgroups of patients with four or more metastatic lymph nodes or less than four nodes involved.
Discussion
In this communication we report an improved histochemical assay for the quantitation of protein-tyrosine phosphatase activity, and find that aberrantly high PTPase activity can be demonstrated in 68% of primary human mammary carcinomas. This finding is in very close agreement with that previously reported (9) and demonstrates that increased PTPase activity in human breast carcinoma is a consistent phenomenon. Invariant co-localization of the increase in PTPase activity in the tumor sections with pathology definitive for carcinoma strongly suggests that the aberration in phosphatase activity coexists with the phenotypic manifestations that constitute carcinoma. It remains to be determined if the abnormally high PTPase activity that is observed is involved in the initiation and maintenance of carcinoma, ensues as a result of the factors that instigate carcinoma, or is merely coincidental with the presence of carcinoma.
Previous reports have shown that the inhibition of tyrosinespecific phosphatase activity in NRK-1 cells by the PTPase-specific inhibitor sodium orthovanadate resulted in a cell phenotype indistinguishable from oncogenic transformation ( 5 ) . The results presented here and elsewhere (8) suggest that a diminution of PTPase activity does not take place in naturally occurring mammary carcinomas, but in contrast is dramaticidly increased over normal levels in the majority of primary mammary carcinomas. Therefore, the incidence of primary carcinoma does not result from diminished PTPase activity. The widespread and heterogeneous increase in PTPase activity in human mammary carcinoma may indicate that increased PTPase activity is a factor that contributes to the initiation of carcinoma, is a general and widespread response to increased PTKase activity, or confers a selective growth advantage to cells as the tumor grows.
No statistically significant association was demonsuated between aberrantly high PTPase activity and a number of established prognostic factors, including grade and stage of disease, survival during a 2-year follow-up, or the expression of the various proto-oncogenes c-erbB-2 (this report), EGFr, or insulin-like growth factor (IGF-I) (9) . Since the median follow-up duration usually reported is 4-5 years (12), it will be of interest to reevaluate the relationship of survival and the PTPase values with longer follow-up. The absence of a statistically significant association between the level of PTPase activity and the expression of human proto-oncogenes, including the c-erbB-2 gene, is not surprising when the complexity of protein phosphorylation and dephosphorylation is considered. Yet it may suggest that the two events may be independent, that the assay used in this study and elsewhere does not, by virtue of the fact that it measures total PTPase activity, accurately measure the level of activity ofthe specific PTPase(s) that is codependent with c-erbB-2 expression, or that PTPase activity is associated with an as yet unidentified proto-oncogene(s). Alternatively, excessive expression of the c-erb-2 tyrosine kinase may bypass or inactivate intermediate factors that interact with or work in unison with kinase-specific PTPases.
It is worth noting that the assay described in this communication measures the total protein-tyrosine-phosphatase activity in cells, and may include phosphatases that cleave P-tyr but whose primary substrate is not 0-phospho-L-tyrosine. The investigation, characterization, and enumeration of PTPases has only been addressed in the last few years, and is most assuredly incomplete. Therefore, the total activity observed in this assay may include proteins that have not yet been identified. In addition, the total PTPase activity as measured by this assay reflects the large number of PTPases that are found in the cell, and may reflect variations in activity in individual protein species within the population while maintaining an overall similar total phosphatase activity. This point may be better addressed when individual marker reagents are available to measure the expression and/or activity of individual proteins within the total population in cells and in tissue sections.
We have observed, in agreement with previous reports, that PTPase activity is aberrantly high in the nuclei of carcinoma cells (9) . Recent theoretical considerations of the number and variety of PTPases indicate that a large number of PTPases may be found within the cell and all of its constituent organelles, in concordance with the findings that PTKases are found in all subcellular fractions of the cell (3). Since only a few of the members of the PTPase family of enzymes have been characterized, it is impossible at the present time to state whether the activity observed in the nucleus is due to the presence there of specific PTPase(s). We note, however, that recent findings demonstrate that eucaryotic nuclear FTPases are involved in the synchronization and regulation of the cell cycle (6) . The observed aberrantly high PTPase activity in the nuclei of human mammary carcinoma cells may be a reflection of the altered regulation of cell growth in oncogenic transformation.
Receptor PTPases are putatively involved in cell-cell recognition and the regulation of cell growth (13) and have been designated, along with non-receptor PTPases, "anti-oncogenes" (3, 8, 14) ; their implied functions include the mediation of "contact inhibition" as well as the capability to counteract the excessive PTKase activity caused by the amplification and/or overexpression of protooncogene PTKases. PTPases may act as a natural defense mecha-nism by which cells protect themselves from aberrantly regulated oncogene protein-tyrosine kinases. The isolation and molecular characterization of specific FTPase genes and their encoded proteins will assist in elucidating the normal function of these enzymes in the growth and regulation of cells, the role that FTPases play in the regulation of F'TKases, and will provide information on their involvement in oncogenic transformation and tumorigenesis.
